Chewable dosage forms containing sitagliptin and metformin
The present invention provides a chewable dosage form having a matrix comprising: a combination of active pharmaceutical ingredients which is metformin hydrochloride and sitagliptin or a pharmaceutically acceptable salt thereof; a fully or partially pregelatinized starch, a polyethylene glycol polymer; a lubricant; an emulsifier; a flavoring agent; and a sweetener. The present invention also provides a method of treating diabetes, e.g., non-insulin dependent (Type 2) diabetes mellitus, comprising administering a therapeutically effective amount of the chewable dosage form to a mammalian patient in need thereof.
1. A chewable dosage form having a matrix comprising:
from 15 to 40 wt. % of a combination of active pharmaceutical ingredients which is metformin hydrochloride and sitagliptin or a pharmaceutically acceptable salt thereof;
from 25 to 45 wt. % of a fully or partially pregelatinized starch;
from 0.5 to 10 wt. % of a polyethylene glycol 8000;
from 5 to 20 wt. % of a lubricant, wherein the lubricant is partially hydrogenated palm kernel oil;
an emulsifier;
a flavoring agent; and
a sweetener;
and
wherein the dosage form is chewable.
2. The chewable dosage form of claim 1 , wherein the emulsifier is glycerol monostearate or cetyl alcohol.
3. The chewable dosage form of claim 1 , wherein the matrix further comprises an acidifier wherein the acidifier is citric acid, malic acid, acetic acid, lactic acid or tartaric acid.
4. The chewable dosage form of claim 1 , wherein the matrix further comprises a humectant, wherein the humectant is glycerin, propylene glycol, or cetyl alcohol.
5. The chewable dosage form of claim 1 , wherein the sweetener is a hydrogenated starch hydrolysate, a sugar alcohol, sucralose, glycyrrhizin or a pharmaceutically acceptable salt thereof, or a combination thereof.
6. The chewable dosage form of claim 1 , wherein the flavoring agent is peppermint.
7. The chewable dosage form of claim 1 , wherein the combination of active pharmaceutical ingredients is 500 mg of metformin hydrochloride and 50 mg of sitagliptin.
8. A method for treating diabetes, comprising administering a therapeutically effective amount of the chewable dosage form of claim 1 to a mammalian patient in need thereof.
9. A method for treating non-insulin dependent diabetes mellitus, comprising administering a therapeutically effective amount of the chewable dosage form of claim 1 to a mammalian patient in need thereof.